Weight Loss

MetaVia Inc. (NASDAQ:MTVA) shares are up during Friday’s premarket session as the company announced a strong global intellectual property portfolio supporting its lead asset, DA-1726. MetaVia revealed that it has secured 39 granted and pending patents in the U.S. and internationally for DA-...

Novo Nordisk A/S (NYSE:NVO) plans to start selling its blockbuster obesity drug Wegovy in vials, marking its latest effort to strengthen its position against rival Eli Lilly and Co. (NYSE:LLY) as competition intensifies in the fast-growing weight-loss market. Currently, Novo markets Wegovy in...

Hoth Therapeutics Inc. (NASDAQ:HOTH) on Tuesday revealed preclinical data from its study on glial cell-derived neurotrophic factor (GDNF) for obesity and metabolic-associated steatotic liver disease (MASLD). The U.S. Veterans Administration (VA) backed the study, which builds on prior research...

Novo Nordisk A/S (NYSE:NVO) said on Monday it has filed a lawsuit against telehealth company Hims & Hers Health Inc. (NYSE:HIMS) for infringing U.S. Patent 8,129,343 with compounded semaglutide products for the U.S. market. • Hims & Hers Health stock is at significant support. What...

Telehealth giant Hims & Hers Health, Inc. (NYSE:HIMS) may have flown too close to the sun and is now under fire on multiple fronts, including federal intervention, criminal investigation and a patent war. Shares of Hims & Hers crashed to new 52-week lows on Monday, under the weight of much...

Novo Nordisk A/S (NYSE:NVO) on Monday said it has filed a lawsuit against telehealth company Hims & Hers Inc. (NYSE:HIMS) for infringing U.S. Patent 8,129,343 with Hims’ compounded semaglutide products for the U.S. market. Novo Nordisk stock also gained momentum as it initiated the...

Novo Nordisk A/S (NYSE:NVO) is trading higher on Friday after falling for two consecutive days on lower-than-expected fiscal 2026 guidance and compounding concerns. • Novo Nordisk stock is showing exceptional strength. What’s behind NVO gains? On Tuesday, the company said it expects...

Eli Lilly and Co. (NYSE:LLY) stock is trading lower on Thursday, possibly on profit-taking after the stock rallied roughly 10% on Wednesday. On Wednesday, Eli Lilly reported fourth-quarter adjusted earnings of $7.54 per share, beating the consensus of $6.67. The company’s sales reached $19.3...

On Thursday, Hims & Hers Health Inc. (NYSE:HIMS) announced Thursday an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Novo Nordisk A/S' (NYSE:NVO) Wegovy. Starting today, eligible customers can access...

Over the last two days, Novo Nordisk A/S (NYSE:NVO) stock has plunged around 18% after the company issued a softer outlook for fiscal 2026. On the other hand, Eli Lilly and Co. (NYSE:LLY) investors cheered the company’s better-than-expected fourth quarter earnings and upbeat fiscal 2026...

Eli Lilly and Co. (NYSE:LLY) stock is trading higher after the company released better-than-expected Q4 earnings and issued fiscal 2026 guidance. Earnings Overview Eli Lilly reported fourth-quarter adjusted earnings of $7.54 per share, beating the consensus of $6.67. The company's sales reached $19...

Novo Nordisk A/S (NYSE:NVO) stock fell Wednesday after the Danish drugmaker issued a softer-than-expected outlook for fiscal 2026. The stock is trading closer to the lower end of the 52-week range of $43.08-$93.80. On Tuesday, the company said it expects adjusted sales growth for 2026, which...

Novo Nordisk A/S (NYSE:NVO) stock is trading lower on Tuesday after the weight-loss drug maker released its 2026 full-year sales and operating profit outlook. 2026 Outlook Novo Nordisk expects reported 2026 sales and operating profit to benefit from a $4.2 billion reversal of 340B Drug Pricing...

On Tuesday, Pfizer Inc. (NYSE:PFE) shared topline data from a mid-stage study for a weight loss drug and reported fourth quarter earnings that beat consensus estimates. Weight Loss Data Pfizer released data from the Phase 2b VESPER-3 study of monthly maintenance dosing of PF'3944 (MET-097i) in...

Novo Nordisk A/S (NYSE:NVO) on Monday shared headline results from the REIMAGINE 2 phase 3 trial from the global REIMAGINE clinical trial program. CagriSema for weight management was submitted to the U.S. Food and Drug Administration (FDA) in December 2025 based on the REDEFINE 1 and REDEFINE 2...